Transcranial Ultrasound Via Sonolucent Cranioplasty After Minimally Invasive Intracerebral Hemorrhage Evacuation
Study Phase: N/A
Recruitment Status: Recruiting
Start Date: September 09, 2022
End Date: September 09, 2024
Inclusion criteria:
- Presence of spontaneous supratentorial ICH ≥20 mL
- Age ≥18 years
- National Institute of Health Stroke Scale (NIHSS) score ≥6
- GCS score 5-15 at presentation
- Undergoing minimally invasive intracerebral hemorrhage evacuation with sonolucent cranioplasty or hemicraniectomy with sonolucent cranioplasty
Exclusion criteria:
- Secondary cause for the ICH, such as an underlying vascular malformation (cavernous malformation, arteriovenous malformation, etc.), aneurysm, neoplasm, hemorrhagic transformation of an underlying ischemic infarct; or venous infarct
- History of osteomyelitis
- History of skull neoplasm
- History of comminuted skull fractures
- Infratentorial hemorrhage
- Midbrain extension/involvement
- Coagulopathy defined as INR > 1.4, elevated aPTT, or concurrent use of direct oral anticoagulants or low molecular weight heparin at ICH onset; known hereditary or acquired hemorrhagic diathesis; coagulation factor deficiency; platelet count < 100x103cells/mm3, or known platelet dysfunction
- Inability to obtain consent from patient or appropriate surrogate (for patients without capacity)
- Evidence of active infection indicated by fever ≥ 100.7F and/or open draining wound at the time of enrolment
- Any comorbid disease or condition expected to compromise survival or ability to complete follow-up assessments through 1 year
- Based on investigator's judgment, the patient does not have the necessary mental capacity to participate or is unwilling to comply with the protocol follow-up appointment schedule
- Active drug or alcohol abuse that, in the opinion of the site investigator, would interfere with adherence to study enrolments
- Pre-existing DNR/DNI status
-
Conditions:
- Cerebral Hemorrhage
- Hemorrhage